Ramachandran Venkitaraman

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2020 · 220 citations · Full text

Effect of the COVID-19 pandemic on cancer treatment and research

Kamal S. Saini, Begoña de las Heras, Javier de Castro et al. · The Lancet Haematology · 2020 · 159 citations · Full text

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Sacha J. Howell, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2022 · 136 citations · Full text

A Randomised Phase 2 Trial of Dexamethasone Versus Prednisolone in Castration-resistant Prostate Cancer

Ramachandran Venkitaraman, David Lorente, Vedang Murthy et al. · European Urology · 2014 · 93 citations

Urology, Oncology, Genitourinary Cancer +9

Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer

Ramachandran Venkitaraman, Karen Thomas, Robert Huddart et al. · British Journal of Urology · 2007 · 79 citations